Exploring a new frontier in cancer treatment: Targeting the ubiquitin and ubiquitin-like activating enzymes

  • Da Silva S
  • Paiva S
  • Lukkarila J
 et al. 
  • 61


    Mendeley users who have this article in their library.
  • 15


    Citations of this article.


The labeling of proteins with small ubiquitin (Ub) and ubiquitin-like (Ubl) modifiers regulates a plethora of activities within the cell, such as protein recycling, cell cycle modifications, and protein translocation. These processes are often overactive in diseased cells, leading to unregulated cell growth and disease progression. Therefore, in systems where Ub/Ubl protein labeling is dysregulated, the development of drugs to selectively and potently disrupt Ub/Ubl protein labeling offers a targeted molecular approach for sensitizing these diseased cells. This Perspective outlines the progress that has been made in the context of inhibitor development for targeting Ub/Ubl pathways.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Sara R. Da Silva

  • Stacey Lynn Paiva

  • Julie L. Lukkarila

  • Patrick T. Gunning

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free